Abstract: A process for the preparation of the calcium salt of heparin containing an amount of sodium by weight not in excess of 0.1% and containing an amount of calcium by weight not less than 9.5% is described, which comprises subjecting a solution of sodium heparinate to dialysis, hyperfiltration (inverse osmosis) or ultrafiltration by means of a semi-permeable membrane and isolating the calcium heparinate with anticoagulant activity essentially equal to the anticoagulant activity of the sodium heparinate. For the ultrafiltration, a membrane may be used in the form of a planar sheet or a membrane in the form of a spiral or "needle" having a molecular nominal cut-off at 20,000 Dalton. For the hyperfiltration (inverse osmosis), a membrane may be used having a rejection of sodium ion between 0 and 75%. For the dialysis, a membrane may be used in the form of multiple sheets or a coiled tube or hollow fibers. A plurality of dialyzers in series or in parallel is used.
Type:
Grant
Filed:
August 11, 1980
Date of Patent:
October 11, 1983
Assignee:
Italfarmaco S.p.A.
Inventors:
Pietro Cremonesi, Giancarlo Sportoletti
Abstract: Pharmaceutical compositions for use in the relief of acute pulmonary edema, different types of shock including anaphylactic shock, shock induced by bacterial endotoxins, and hyperfibrinolysis induced by substances which activate plasminogen, consist of solutions of an ester of L-arginine with an aliphatic alcohol in water at a pH between 5.5 and 8.5. The compositions may be provided in unit dosage form containing 0.25-100 mg of active substance per kilogram of body weight of the subject in need of treatment and are administered through the parenteral route. The esters may be provided in the form of a salt with a pharmaceutically acceptable organic or inorganic acid. The esters may be with methyl or ethyl alcohol. The compositions are more effective than aspirin and aprotinin.
Abstract: Enzyme immobilization is carried out be adding to a suspension of polysaccharide in aqueous medium, a vinyl monomer and an enzyme, then a catalyst comprising a metallic salt, and irradiating the resulting mixture with ultraviolet light to cause polymerization and form a copolymer of the polysaccharide having enzymatic activity. The metallic salt is preferably a ferric salt and the vinyl monomer is preferably methylacrylate, glycidylmethacrylate, acrylonitride, bis-acyloylpiperazine or symmetrical N, N', N"-trisacryloyl-hexahydrotriazine.
Abstract: Pharmaceutical compositions exhibiting antiphlogistic, antipyretic, analgesic activity and high gastroenteric tolerance are described. The active ingredient is imidazole salicylate of chemical formula (I).
Abstract: Pharmaceutical compositions for use in the relief of acute pulmonary edema, different types of shock including anaphylactic shock, shock induced by bacterial endotoxins, and hyperfibrinolysis induced by substances which activate plasminogen, consist of solutions of an ester of L-arginine with an aliphatic alcohol in water at a pH between 5.5 and 8.5. The compositions may be provided in unit dosage form containing 0.25-100 mg of active substance and are administered through the parenteral route. The esters may be provided in the form of a salt with a pharmaceutically acceptable organic or inorganic acid. The esters may be with methyl or ethyl alcohol. The compositions are more effective than aspirin and aprotinin.
Abstract: A novel reactor for enzymatic reactions comprises a flow cell which is constituted by two semi-blocks having a planar surface. The enzyme is immobilized on one of the semi-blocks while a thin channel is provided on the face of the other semi-block. The two semi-blocks are hermetically closed. The substrate solution follows a tangential motion and travels with a laminar flow. The reactor permits to achieve 90% contact with the enzyme and may be used continuously.
Abstract: Pharmaceutical compositions containing a corticosteroid and an ester of L-arginine with an aliphatic alcohol exhibit a synergistic effect in the protection against shock. The corticosteroid may be 6-.alpha.-methylprednisolone-21-hemisuccinate sodium salt and the L-arginine ester may be the methyl ester in the form of the hydrochloride salt.